Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase

Biochemical Pharmacology

Volumn 64, Issue 12, 2002, Pages 1767-1775

  Albert, Dana ^a   Zündorf, Ilse ^a   Dingermann, Theo ^a   Müller, Walter E ^a   Steinhilber, Dieter ^a   Werz, Oliver ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

5 Lipoxygenase; Cyclooxygenase; Hyperforin; Hypericum perforatum; Leukotriene; Prostaglandin

Indexed keywords

12 HYDROXYHEPTADECATRIENOIC ACID; ACETYLSALICYLIC ACID; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CALCIMYCIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; HYPERFORIN; HYPERICUM PERFORATUM EXTRACT; IONOPHORE; LEUKOTRIENE; THROMBIN; UNCLASSIFIED DRUG; ZILEUTON;

ARTICLE; CATALYSIS; CELL ISOLATION; CELL STIMULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PURIFICATION; ENZYME REPRESSION; HUMAN; HUMAN CELL; IC 50; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE;

ANTI-BACTERIAL AGENTS; ARACHIDONATE 5-LIPOXYGENASE; BICYCLO COMPOUNDS; BLOOD PLATELETS; CELLS, CULTURED; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENZYME INHIBITORS; HUMANS; HYPERICUM; ISOENZYMES; LEUKOCYTES, MONONUCLEAR; MEMBRANE PROTEINS; PHLOROGLUCINOL; PLANT EXTRACTS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; TERPENES;

EID: 0037114483     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01387-4     Document Type: Article

References (43)

1. Gaster B., Holroyd J. St. John's wort for depression: a systematic review. Arch. Intern. Med. 160(2):2000;152-156.
2. Greeson J.M., Sanford B., Monti D.A. St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology (Berl.). 153(4):2001;402-414.
3. Di Carlo G., Borrelli F., Ernst E., Izzo A.A. St. John's wort: Prozac from the plant kingdom. Trends Pharmacol. Sci. 22(6):2001;292-297.
4. Linde K., Ramirez G., Mulrow C.D., Pauls A., Weidenhammer W., Melchart D. St. John's wort for depression - an overview and meta-analysis of randomised clinical trials. Br. J. Med. 313(7052):1996;253-258.
5. Laakmann G., Schule C., Baghai T., Kieser M. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry. 31(Suppl. 1):1998;54-59.
6. Chatterjee S.S., Bhattacharya S.K., Wonnemann M., Singer A., Muller W.E. Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci. 63(6):1998;499-510.
7. Jensen A.G., Hansen S.H., Nielsen E.O. Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity. Life Sci. 68(14):2001;1593-1605.
8. +. J. Pharmacol. Exp. Ther. 290(3):1999;1363-1368.
9. Schempp C.M., Pelz K., Wittmer A., Schopf E., Simon J.C. Antibacterial activity of hyperforin from St. John's wort, against multiresistant Staphylococcus aureus and Gram-positive bacteria. Lancet. 353(9170):1999;2129.
10. Fiebich B.L., Heinrich M., Langosch J.M., Kammerer N., Lieb K. Antibacterial activity of hyperforin from St. John's wort. Lancet. 354(9180):1999;777.
11. Simon J, Schempp C, Schoepk E, Simon-Haarhaus B. Hyperforin as cytostatic agent and hyperforin ointment or cream as application form. PCT Int Appl 2000;39.
12. Schempp C.M., Winghofer B., Ludtke R., Simon-Haarhaus B., Schopf E., Simon J.C. Topical application of St. John's wort (Hypericum perforatum L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells. Br. J. Dermatol. 142(5):2000;979-984.
13. Moore L.B., Goodwin B., Jones S.A., Wisely G.B., Serabjit-Singh C.J., Willson T.M., Collins J.L., Kliewer S.A. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. U.S.A. 97(13):2000;7500-7502.
14. Otto J.C., Smith W.L. Prostaglandin endoperoxide synthases-1 and -2. J. Lipid Mediators Cell Signal. 12(2/3):1995;139-156.
15. Samuelsson B., Dahlén S.-E., Lindgren J.-Å., Rouzer C.A., Serhan C.N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 237:1987;1171-1176.
16. Steinhilber D. 5-Lipoxygenase: a target for antiinflammatory drugs revisited. Curr. Med. Chem. 6:1999;69-83.
17. Parente L. Pros and cons of selective inhibition of cyclooxygenase-2 versus dual lipoxygenase/cyclooxygenase inhibition: is two better than one? J. Rheumatol. 28(11):2001;2375-2382.
18. Feldman M., McMahon A.T. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann. Intern. Med. 132(2):2000;134-143.
19. Vane J.R., Botting R.M. Mechanism of action of anti-inflammatory drugs. Scand. J. Rheumatol. Suppl. 102:1996;9-21.
20. Celotti F., Laufer S. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol. Res. 43(5):2001;429-436.
21. Bertolini A., Ottani A., Sandrini M. Dual acting anti-inflammatory drugs: a reappraisal. Pharmacol. Res. 44(6):2001;437-450.
22. Werz O., Brungs M., Steinhilber D. Purification of transforming growth factor beta1 from human platelets. Pharmazie. 51(11):1996;893-896.
23. Brungs M., Rådmark O., Samuelsson B., Steinhilber D. Sequential induction of 5-lipoxygenase gene expression and activity in Mono Mac 6 cells by transforming growth factor-beta and 1,25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. U.S.A. 92(1):1995;107-111.
24. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand. J. Clin. Lab Invest. 97(Suppl. 21):1968;77-89.
25. Werz O., Steinhilber D. Selenium-dependent peroxidases suppress 5-lipoxygenase activity in B-lymphocytes and immature myeloid cells - the presence of peroxidase-insensitive 5-lipoxygenase activity in differentiated myeloid cells. Eur. J. Biochem. 242(1):1996;90-97.
26. Hammarberg T., Zhang Y.Y., Lind B., Rådmark O., Samuelsson B. Mutations at the C-terminal isoleucine and other potential iron ligands of 5-lipoxygenase. Eur. J. Biochem. 230(2):1995;401-407.
27. Werz O., Szellas D., Henseler M., Steinhilber D. Nonredox 5-lipoxygenase inhibitors require glutathione peroxidase for efficient inhibition of 5-lipoxygenase activity. Mol. Pharmacol. 54:1998;445-451.
28. Brune K., Reinke M., Lanz R., Peskar B.A. Monoclonal antibodies against E- and F-type prostaglandins. High specificity and sensitivity in conventional radioimmunoassays. FEBS Lett. 186(1):1985;46-50.
29. Yamamoto S, Yokota K, Tonai T, Shono F, Hayashi Y. Enzyme Immunoassay. Prostaglandins and Related Substances - A Practical Approach. Oxford: IRL Press; 1987.
30. Berg J., Christoph T., Widerna M., Bodenteich A. Isoenzyme-specific cyclooxygenase inhibitors: a whole cell assay system using the human erythroleukemic cell line HEL and the human monocytic cell line Mono Mac 6. J. Pharmacol. Toxicol. Methods. 37(4):1997;179-186.
31. Biber A., Fischer H., Romer A., Chatterjee S.S. Oral bioavailability of hyperforin from Hypericum extracts in rats and human volunteers. Pharmacopsychiatry. 31(Suppl. 1):1998;36-43.
32. Bell R.L., Lanni C., Malo P.E., Brooks D.W., Stewart A.O., Hansen R., Rubin P., Carter G.W. Preclinical and clinical activity of zileuton and A-78773. Ann N.Y. Acad. Sci. 696:1993;205-215.
33. Carter G.W., Young P.R., Albert D.H., Bouska J., Dyer R., Bell R.L., Summers J.B., Brooks D.W. 5-Lipoxygenase inhibitory activity of zileuton. J. Pharmacol. Exp. Ther. 256(3):1991;929-937.
34. Nahrstedt A., Butterweck V. Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry. 30(Suppl. 2):1997;129-134.
35. Manev H., Uz T., Sugaya K., Qu T. Putative role of neuronal 5-lipoxygenase in an aging brain. FASEB J. 14(10):2000;1464-1469.
36. Schror K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin. Thromb. Hemost. 23(4):1997;349-356.
37. DeWitt D.L. Cox-2-selective inhibitors: the new super aspirins. Mol. Pharmacol. 55(4):1999;625-631.
38. Masferrer J.L., Zweifel B.S., Manning P.T., Hauser S.D., Leahy K.M., Smith W.G., Isakson P.C., Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. U.S.A. 91(8):1994;3228-3232.
39. Langenbach R., Morham S.G., Tiano H.F., Loftin C.D., Ghanayem B.I., Chulada P.C., Mahler J.F., Lee C.A., Goulding E.H., Kluckman K.D.et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 83(3):1995;483-492.
40. Wallace J.L., Bak A., McKnight W., Asfaha S., Sharkey K.A., MacNaughton W.K. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology. 115(1):1998;101-109.
41. Nickerson-Nutter C.L., Medvedeff E.D. The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation. Arthritis Rheum. 39(3):1996;515-521.
42. Laufer S., Tries S., Augustin J., Dannhardt G. Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase. Arzneimittelforschung. 44(5):1994;629-636.
43. Obach R.S. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J. Pharmacol. Exp. Ther. 294(1):2000;88-95.